Cuts in NIH grants and the threat of more are discouraging investment and may drive trials out of the United States.

Moderna will not be developing a vaccine to protect against bird flu — at least on the federal government’s dime. The U.S.

The department cited Moderna’s use of the messenger RNA technology, which it said “remains under-tested,” for the ...

Meanwhile, Moderna has progressed nicely on its cost cutting program, and beyond this year, plans to reduce as much as $1.7 ...

A study in Nature Aging from researchers at the UC Davis School of Medicine has identified specific microRNAs—non-coding RNAs ...

WASHINGTON — mRNA, a Nobel-winning technology harnessed by Trump officials to create Covid shots in record time, is becoming ...

Overview of RNA Therapeutics MarketThe Global RNA Therapeutics Market is valued at USD 10.9 Billion in 2024 and is projected ...

UC Irvine researchers conducted a study to better understand the molecular basis of amyotrophic lateral sclerosis (ALS), a ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Messenger RNA technology offers a faster way to develop vaccines to address or prepare for pandemics, and Moderna’s vaccine ...

A new type of mRNA vaccine is more adaptable to mutating viruses like SARS-CoV-2 and the bird flu, according to research from ...

Moderna (MRNA) stock in focus as the U.S. FDA approved its next-gen COVID-19 vaccine, mNEXSPIKE,. Read more here.